109155 ⎘
Structure or type of the nucleic acid; Chemical structure of the backbone
Sub-classes:THERAPEUTIC OLIGONUCLEOTIDES TO CORRECT CYSTIC FIBROSIS MUTATIONS
#2OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF
#3Compositions and Methods for Correcting Limb Girdle Muscular Dystrophy Type 2C Using Exon Skipping
#4COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#5RNAI AGENTS FOR INHIBITING EXPRESSION OF HUNTINGTIN (HTT), COMPOSITIONS THEREOF, AND METHODS OF USE
#6FACTOR XII (HAGEMAN FACTOR) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), AND KININOGEN 1 (KNG1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#7GALNAC COMPOUND CONTAINING RIBOSE RING OR ITS DERIVATIVE STRUCTURE AND OLIGONUCLEOTIDE CONJUGATE THEREOF
#8COMPOUNDS AND METHODS FOR REDUCING PRION EXPRESSION
#9PRNP RNAi AGENTS
#10NUCLEIC ACID COMPOUNDS
#11CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#12COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#13Conjugated Antisense Compounds and Their Use
#14BBB-CROSSING LIPID LIGAND OF HETERO NUCLEIC ACID
#15CHIRAL DESIGN
#16AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE CONJUGATION APPROACH
#17Oligonucleotide Terminal Phosphate Derivatives and Method of Use
#18NUCLEIC ACID-POLYPEPTIDE NANO-PHARMACEUTICAL COMPOSTION FOR TREATING AND PREVENTING HUMAN PAPILLOMA VIRUS INFECTION
#19Guide RNA Constructs for Therapeutic Gene Editing
#20P-ETHOXY NUCLEIC ACIDS FOR LIPOSOMAL FORMULATION
#21COMPOSITIONS AND METHODS FOR TREATMENT OF PRION DISEASES
#22POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF
#23MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT
#24LNCRNA TRANSCRIPTS IN MELANOMAGENESIS
#25MULTIPLEXING TARGETING LIGANDS THROUGH CLICK CHEMISTRY AT THE ANOMERIC SITE OF SUGARS
#26ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF
#27ATXN2 RNA INTERFERENCE AGENTS
#28Methods and Compositions for RNA-Directed Target DNA Modification and For RNA-Directed Modulation of Transcription
#29Methods and Compositions for RNA-Directed Target DNA Modification and for RNA-Directed Modulation of Transcription
#30COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA
#31PIKFYVE ANTISENSE OLIGONUCLEOTIDES
#32COMPOSITIONS AND METHODS OF MODULATING LONG NONCODING TRANSCRIPTS ASSOCIATED WITH ARDS INDUCED PULMONARY FIBROSIS
#33TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF UNC13A GENE TRANSCRIPTS
#34Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same
#35Methods and Compositions for RNA-Directed Target DNA Modification and For RNA-Directed Modulation of Transcription
#36COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#37METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53
#38Compositions and methods for modulating apolipoprotein (a) expression
#39COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#40COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING
#41COMPOUNDS AND METHODS FOR REDUCING TAU EXPRESSION
#42Selective Antisense Compounds and Uses Thereof
#43COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#44Conjugated antisense compounds and their use
#45CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#46CHIRAL CONTROL
#47OPTIMIZED 2'- MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE
#48NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE
#49DOUBLE-STRANDED SIRNA HAVING PATTERNED CHEMICAL MODIFICATIONS
#50SYNERGISTIC EFFECT OF SMN1 AND MIR-23A IN TREATING SPINAL MUSCULAR ATROPHY
#51FACTOR XII (HAGEMAN FACTOR) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), AND KININOGEN 1 (KNG1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#52COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#53Oligonucleotides conjugated to oleic acid and uses thereof
#54COMPOUNDS AND METHODS FOR MODULATING PMP22
#55OLIGONUCLEOTIDES FOR MLH1 MODULATION
#56Compositions and methods of treating facioscapulohumeral muscular dystrophy
#57COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION
#58Compositions and methods of treating facioscapulohumeral muscular dystrophy
#59Compositions and methods of treating Facioscapulohumeral muscular dystrophy
#60COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF
#61MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT
#62INTERFERON- INDUCING OLIGONUCLEOTIDE DUPLEXES AND METHODS OF USE
#63UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES
#64NUCLEIC ACID MOLECULE HAVING IMPROVED STABILITY, AND USE THEREOF
#65METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA DIRECTED MODULATION OF TRANSCRIPTION
#66ANTISENSE THERAPEUTICS FOR THE TREATMENT OF CORONAVIRUS
#67COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING
#68RIG-I Agonists and Methods of Using Same
#69COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#70DESIGN METHOD FOR OPTIMIZED RIG-I LIGANDS
#71HAIRPIN STRUCTURE NUCLEIC ACID MOLECULES CAPABLE OF MODULATING TARGET GENE EXPRESSION AND USES THEREOF
#72Polymerizable compound, compound, and method for producing boranophosphate oligomer
#73EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#74ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED METHODS
#754′-phosphate analogs and oligonucleotides comprising the same
#76SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#77Compounds and methods for modulating factor XII
#78PIKFYVE antisense oligonucleotides
#79OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF
#80COMPOUNDS AND METHODS FOR REDUCING SNCA EXPRESSION
#81DOUBLE-STRANDED NUCLEIC ACID COMPLEX AND USE THEREOF
#82Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
#83ANTISENSE OLIGONUCLEOTIDE THERAPY FOR CANCER
#84COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#85Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#86Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#87Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#88Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#89EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#90COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION
#91Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same
#92COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR MODULATING EXPRESSION OF DUX4
#93POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF
#94P-ethoxy nucleic acids for STAT3 inhibition
#95COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING
#965'-Cyclo-Phosphonate Modified Nucleotides
#97METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#98Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#99Compositions and their uses directed to huntingtin
#100Targeting Ligands
#101Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#102Compounds and methods for reducing prion expression
#103Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#104AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#105COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#106Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#107Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#108Compositions and methods of treating Facioscapulohumeral muscular dystrophy
#109P-ethoxy nucleic acids for liposomal formulation
#110Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#111Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#112Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#113Compositions and methods of treating Facioscapulohumeral muscular dystrophy
#114MULTIPLEXED SHRNAS AND USES THEREOF
#115Combination therapy with liposomal antisense oligonucleotides
#116Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#117Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#118Nucleic acid-drug complex and use thereof
#119RIG-I Agonists and Methods of Using Same
#120Oligonucleotide compositions and methods thereof
#121Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#122COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
#123BBB-crossing lipid ligand of hetero nucleic acid
#124Methods for Improving Leptin Sensitivity for the Treatment of Obesity and Diabetes
#125ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY
#126COMPOSITIONS AND METHODS
#127Chiral control
#128P-ethoxy nucleic acids for BCL2 inhibition
#129P-ETHOXY NUCLEIC ACIDS FOR IGF-1R INHIBITION
#130Chiral design
#131Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#132Method of nonspecific target capture of nucleic acids
#133HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF
#134Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#135Compositions and methods for modulating apolipoprotein (a) expression
#136Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#137Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#138Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#139Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#140Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#141Compositions and Methods for Correcting Limb Girdle Muscular Dystrophy Type 2C Using Exon Skipping
#142COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#143METHOD FOR ACTIVATING P21 GENE EXPRESSION
#144COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#145Conjugated antisense compounds and their use
#146POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS
#147Compounds and methods for reducing SNCA expression
#148Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#149Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#150Antisense oligonucleotides targeting alpha-synuclein and uses thereof
#151Peptide phosphorodiamidate morpholino oligomers plant delivery to reduce pathogens and insect pests
#152Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#153Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#154Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#155Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof
#156EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#157Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
#158Compositions and their uses directed to huntingtin
#159Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#160Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#161COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA
#162Compositions and methods for treating transposon associated diseases
#163SMALL GUIDE ANTISENSE NUCLEIC ACID AND USE THEREOF
#164Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA
#165Pan-genotypic agents against influenza virus and methods of using the same
#166COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#167Compounds and methods for reducing Tau expression
#168Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#169Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof
#170ANTISENSE NUCLEIC ACID FOR TREATING AMYOTROPHY
#171P-ethoxy nucleic acids for liposomal formulation
#172Methods and compositions for managing vascular conditions
#173POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF
#174Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#175SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
#176P-ethoxy nucleic acids for STAT3 inhibition
#177Combination therapy with liposomal antisense oligonucleotides
#178Aptamers for personal care applications
#179Methods of selecting therapeutic molecules
#180Conjugated antisense compounds and their use
#181Oligomeric compounds comprising α-β-constrained nucleic acid
#182Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#183TNF-alpha-binding aptamer, and therapeutic use for same
#184Piston arrangement
#185Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
#186Compounds and methods for enhanced cellular uptake
#187Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#188Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#189Polymerizable compound, compound, and method for producing boranophosphate oligomer
#190Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#191Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#192Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#193Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#194Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#195Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#196Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#197Targeting ligands
#198Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
#199MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
#200Oligonucleotides, compositions and methods thereof
#2014'-phosphate analogs and oligonucleotides comprising the same
#202Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#203METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#204METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#205METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#206METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#207Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#208Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#209Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#210Methods and compositions or RNA-directed target DNA modification and for RNA-directed modulation of transcription
#211Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#212Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#213Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#214Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#215Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#216Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#217Chiral design
#218Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53
#219Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#220In vivo gene silencing by chemically modified and stable siRNA
#2215′-cyclo-phosphonate modified nucleotides
#222METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#223Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#224COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#225METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#226METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#227METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#228METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#229Anti-ADAM33 oligonucleotides and related methods
#230Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
#231Methods and compositions for managing vascular conditions
#232Organic compositions to treat beta-ENaC-related diseases
#233Compositions and their uses directed to huntingtin
#234Antisense composition and method for treating muscle atrophy
#235Argonaute protein-double stranded RNA complexes and uses related thereto
#236Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#237Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#238Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#239METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#240METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#241Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#242Induced exon inclusion in spinal muscle atrophy
#243Compositions and methods for modulating apolipoprotein (a) expression
#244Compositions and methods for modulating apolipoprotein C-III expression
#245Compositions and their uses directed to huntingtin
#246Antisense nucleic acid for treating amyotrophy
#247UNA oligomers for therapeutics with prolonged stability
#248Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#249Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
#250Methods and compositions for selecting siRNA of improved functionality
#251Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)
#2522′ fluoro-modified RNAs as immunostimulators
#253Compositions and methods for inhibiting gene expression of LPA
#254Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
#255P-ethoxy nucleic acids for liposomal formulation
#256Compounds and methods for reducing Tau expression
#257Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
#258Targeting ligands
#259Compositions and methods for modulating Tau expression
#260Compositions and methods for modulating TTR expression
#261IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
#262Compositions for modulating expression of C9ORF72 antisense transcript
#263Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#264COMPOUNDS AND METHODS FOR IMPROVED CELLULAR UPTAKE OF ANTISENSE COMPOUNDS
#265COMPOSITIONS AND METHODS
#266EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#267Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#268Organic compositions to treat Beta-ENaC-related diseases
#269Method for RGEN RNP delivery using 5′-phosphate removed RNA
#270Pharmaceutical composition for treatment of cancer comprising RNA oligonucleotide
#271KRAS nucleic acids and uses thereof
#272Methods of Inducing Exon Skipping
#273Chiral control
#274Methods of Inducing Exon Skipping
#275Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#276Multiplexed shRNAs and uses thereof
#277Antiviral agent comprising RNA oligonucleotide
#278IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
#279Polynucleotide agents targeting complement component C5 and methods of use thereof
#280Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#281Modified oligonucleotides for telomerase inhibition
#282POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS
#283Oligonucleotide end caps
#284p-Ethoxy nucleic acids for liposomal formulation
#285Compounds and methods for enhanced cellular uptake
#286Compositions and methods for inhibiting gene expression of LPA
#287Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#288ANTISENSE OLIGOMERS AND METHODS FOR TREATING SMN-RELATED PATHOLOGIES
#289Oligomeric compounds comprising alpha-beta-constrained nucleic acid
#290METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53
#291Crosslinked nucleoside and nucleotide
#292Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#293Chiral design
#294Compositions and their uses directed to huntingtin
#295Modulation of Exon Recognition in Pre-mRNA By Interfering with the Secondary RNA Structure
#296CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
#297RNAi-Related Inhibition of TNF-alpha Signaling Pathway for Treatment of Ocular Angiogenesis
#298Nucleic acid inducing RNA interference modified for preventing off-target, and use thereof
#299Antisense composition and method for treating muscle atrophy
#300Organic compositions to treat beta-ENaC-related diseases